Research graph
References from Patent Litigation and the Timing of Entry by Biologic Biosimilars Compared to Small Molecule Generics in the US, 2015–2025. Local targets link to admitted publications; unresolved targets remain external evidence.
Unresolved reference
External reference
Unresolved reference
External reference
Cancer Drug Trastuzumab and Its Biosimilars Compete on Price for Market Share
10.1377/hlthaff.2022.01448 · 2023 · External reference
Unresolved reference
External reference
US Trends in Anticancer Medicine Pricing and the Impact of Competition, 2014–20
10.1377/hlthaff.2023.01244 · 2024 · External reference
Projections of US Prescription Drug Spending and Key Policy Implications
10.1001/jamahealthforum.2020.1613 · 2021 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
No Free Launch: At-Risk Entry by Generic Drug Firms
10.1080/13571516.2022.2132808 · 2022 · External reference
The Generic Exclusivity Period and the Market Life of Drugs
10.1080/13571516.2026.2621414 · 2026 · External reference
Generic Entry Before the Agreed-Upon Date in Pharmaceutical Patent Settlements
10.1093/joclec/nhaa007 · 2020 · External reference
Using Stock Price Movements to Estimate the Harm from Collusive Drug Patent Litigation Settlements
10.1016/j.jhealeco.2025.103054 · 2025 · External reference
Activating Actavis
2013 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Biosimilar Competition: Early Learning
10.1002/hec.4471 · 2022 · External reference
The Patent Trap: The Struggle for Competition and Affordability in the Field of Biologic Drugs
2021 · External reference
Unresolved reference
External reference
Generic Competition and Market Exclusivity Periods in Pharmaceuticals
10.1002/mde.1356 · 2007 · External reference
Continuing Trends in US Brand-Name and Generic Drug Competition
10.1080/13696998.2021.1952795 · 2021 · External reference
Evergreening, Patent Challenges, and Effective Market Life in Pharmaceuticals
10.1016/j.jhealeco.2012.01.004 · 2012 · External reference
Patents, Innovation, and Competition in Pharmaceuticals: The Hatch-Waxman Act After 40 Years
10.1257/jep.20241423 · 2025 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Unresolved reference
External reference
Biosimilarity and Interchangeability in the Biologics Price Competition and Innovation Act of 2009 and FDA's 2012 Draft Guidance for Industry
10.1089/blr.2013.9884 · 2013 · External reference
Unresolved reference
External reference
Ignoring Patents
2008 · External reference
The Law of 180-Day Exclusivity
2016 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Misinformation About Interchangeable Biosimilars Undermines US Health Policy, Physician Confidence, and Patient Health
10.5639/gabij.2024.1302.009 · 2024 · External reference
Use, Spending, and Prices of Adalimumab Following Biosimilar Competition
10.1001/jamahealthforum.2024.3964 · 2024 · External reference
Unresolved reference
External reference
The Supreme Court Ruling in Sandoz v. Amgen: A Victory for Follow-On Biologics
10.1001/jamainternmed.2017.6145 · 2018 · External reference
Biosimilars and Follow-On Products in the United States: Adoption, Prices, and Users
10.1377/hlthaff.2020.02239 · 2021 · External reference
‘Purple Book’ Patent Listing Under Biological Product Patent Transparency Act: What Is Required, and What to Expect?
2021 · External reference
No Parking Here: A Review of Generic Drug 180-Day Exclusivity and Recent Reform Proposals
2021 · External reference
Barriers to US Biosimilar Market Growth: Lessons from Biosimilar Patent Litigation
10.1377/hlthaff.2020.02484 · 2021 · External reference
